Table 2.
Results of the proportional hazards model for all cause mortality and cardiovascular mortality (n = 1760) in relation to allopurinol exposure, showing relative hazard with 95% confidence intervals in brackets
| All cause mortality (n=971) | Cardiovascular mortality (n=588) | |||
| Unadjusted | Adjusted | Unadjusted | Adjusted | |
| Allopurinol exposure | ||||
| Recent low dose v never | 0.96 (0.70 to 1.33) | 0.90 (0.65 to 1.25) | 1.09 (0.73 to 1.61) | 0.97 (0.65 to 1.46) |
| Longstanding low dose v never | 2.37 (1.73 to 3.24)**** | 2.04 (1.43 to 2.81)** | 2.82 (1.94 to 4.10)**** | 2.40 (1.63 to 3.52)**** |
| Longstanding high dose v never | 1.25 (0.87 to 1.79) | 1.20 (0.83 to 1.74) | 1.77 (1.20 to 2.63)*** | 1.68 (1.12 to 2.53)** |
| Longstanding high dose v longstanding low dose | 0.53 (0.33 to 0.84)*** | 0.59 (0.37 to 0.95)** | 0.63 (0.37 to 1.07)* | 0.70 (0.41 to 1.20) |
| Loop diuretic dose | ||||
| Medium v low | 1.54 (1.34 to 1.76)**** | 1.42 (1.29 to 1.72)**** | 1.50 (1.26 to 1.79)**** | 1.43 (1.19 to 1.72)**** |
| High v low | 1.91 (1.47 to 2.48)**** | 2.05 (1.55 to 2.71)**** | 2.03 (1.47 to 2.81)**** | 2.02 (1.42 to 2.87)**** |
| Age (+ 10 years) | 1.50 (1.41 to 1.60)**** | 2.07 (1.91 to 2.25)**** | 1.35 (1.25 to 1.46)**** | 1.32 (1.20 to 1.44)**** |
| Men v women | 1.16 (1.03 to 1.32)** | 1.46 (1.36 to 1.57)**** | 1.08 (0.92 to 1.27) | 1.19 (1.00 to 1.41)* |
| Social deprivation (+ 1 category) | 0.97 (0.93 to 1.01)* | 1.04 (1.00 to 1.09)* | 0.99 (0.93 to 1.04) | 1.05 (0.99 to 1.11)* |
| Number of prior MIs (+ 1) | 0.98 (0.92 to 1.04) | 1.10 (1.03 to 1.18)*** | 1.02 (0.94 to 1.10) | 1.10 (1.01 to 1.20)** |
| Diabetes | 0.25 (0.18 to 0.37)**** | 0.28 (0.20 to 0.41)**** | 0.26 (0.16 to 0.42)**** | 0.27 (0.17 to 0.44)**** |
| History | ||||
| Use of NSAIDs | 1.36 (1.05 to 1.76)** | 1.29 (0.99 to 1.68)* | 1.50 (1.09 to 2.06)** | 1.37 (0.99 to 1.89)* |
| Use of thiazides | 1.23 (0.94 to 1.61) | 1.15 (0.88 to 1.51) | 1.10 (0.76 to 1.58) | 1.03 (0.72 to 1.49) |
| Respiratory illness | 1.57 (1.38 to 1.79)**** | 1.32 (1.16 to 1.52)**** | 1.33 (1.12 to 1.58)*** | 1.13 (0.94 to 1.35) |
| Renal disease | 1.16 (0.95 to 1.41) | 0.94 (0.77 to 1.14) | 1.22 (0.95 to 1.56) | 1.04 (0.81 to 1.33) |
| Hypertension | 1.10 (0.85 to 1.42) | 1.16 (0.89 to 1.52) | 1.23 (0.90 to 1.68) | 1.19 (0.86 to 1.64) |
| Drugs in concurrent use | ||||
| Aspirin | 0.64 (0.56 to 0.72)**** | 0.69 (0.60 to 0.79)**** | 0.68 (0.58 to 0.80)**** | 0.73 (0.62 to 0.86)**** |
| Anticoagulants | 0.70 (0.55 to 0.89)*** | 0.67 (0.52 to 0.86)*** | 0.76 (0.56 to 1.01)* | 0.66 (0.49 to 0.90)*** |
| ACE inhibitors | 0.85 (0.75 to 0.97)** | 0.84 (0.73 to 0.98)** | 1.03 (0.87 to 1.22) | 0.97 (0.80 to 1.17) |
| β Blockers | 0.41 (0.34 to 0.51)**** | 0.55 (0.45 to 0.69)**** | 0.49 (0.38 to 0.62)**** | 0.61 (0.48 to 0.79)**** |
| Nitrates | 0.74 (0.65 to 0.84)**** | 0.84 (0.74 to 0.97)** | 0.79 (0.67 to 0.94)*** | 0.86 (0.72 to 1.03)* |
| Digoxin | 1.36 (1.19 to 1.57)**** | 1.09 (0.94 to 1.27) | 1.51 (1.27 to 1.80)**** | 1.24 (1.03 to 1.50)** |
| K+ sparing diuretics | 1.03 (0.90 to 1.17) | 0.83 (0.72 to 0.95)*** | 0.94 (0.80 to 1.11) | 0.83 (0.69 to 0.99)** |
| Antiarrhythmics | 0.79 (0.57 to 1.09) | 0.74 (0.53 to 1.03)* | 0.95 (0.65 to 1.40) | 0.88 (0.60 to 1.31) |
*p < 0.1; **p < 0.05; ***p< 0.01; ****p < 0.001.